Drug Profile

CK 0802

Alternative Names: CK-0802

Latest Information Update: 28 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cellenkos
Class Immunotherapies; T lymphocyte cell therapies
Mechanism of Action T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Lung disorders
No development reported SARS-CoV-2 acute respiratory disease

Most Recent Events

28 Oct 2023 No recent reports of development identified for phase-I development in SARS-COV-2 acute respiratory disease in USA (IV, Infusion)
04 Jul 2023 Phase-I clinical trials in Lung disorders (IV) prior to July 2023 (Cellenkos pipeline, July 2023)
04 Jul 2023 Cellenkos completes a phase-I trial in Lung disorders in an undisclosed location (IV) prior to July 2023 (Cellenkos pipeline, July 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com